Arcutis Biotherapeutics, a Westlake Village biopharmaceutical company specializing in topical treatments for psoriasis, has proposed terms for its plan to go public.

The company intends to raise $125 million from the sale of its common stock with an initial public offering price between $15 and $17 a share, according to an amended registration statement filed with the Securities and Exchange Commission on Tuesday...

Join our Membership to get the full story.

Are you a current Member? Sign In